Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer (NCT06698458)
A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-center clinical study enrolling up to 50 participants. The primary objective of the study is to evaluate the safety of Alpha DaRT in combination with chemotherapy, based on the cumulative incidence rate, severity and outcome of device related AEs. Classification of AEs will be done according to CTCAE V6. The secondary objectives of the study are to: * Assess efficacy of the Alpha DaRT sources in combination with chemotherapy, determined by overall and progression-free survival. * Assess pain control * Assess rate of surgical resection in Cohort 1.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years to 120 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- City of Hope — Goodyear, Arizona
- Honor Health — Scottsdale, Arizona
- Cedars-Sinai — Los Angeles, California
- Advent Health Cancer Institute — Orlando, Florida
- Emory University — Atlanta, Georgia
- Bassett Healthcare Network — Cooperstown, New York
- NYU Langone Health — New York, New York
- Lenox hill Hospital — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Texas Oncology — Houston, Texas
- Baylor College of Medicine — Houston, Texas
- University Cancer and Diagnostic — Houston, Texas
- Jewish General Hospital — Montreal, Quebec
- Hadassah Ein Kerem — Jerusalem,
📞 Contact the Study Coordinator
Phone: +972-2-3737-7000
Email: LironD@alphatau.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreatic Cancer
- A Study of the Life Changes Experienced by Patients With Pancreatic Cancer — New York, New York
- Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer — Baltimore, Maryland
- Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma — Hartford, Connecticut
- Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer — Philadelphia, Pennsylvania
- Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer — Basking Ridge, New Jersey
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas — Baltimore, Maryland
Explore by condition: All Pancreatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.